-

Mispro Promotes Yohan Tessier to President and Chief Operating Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mispro, a leading provider of contract vivarium research space and services, has appointed Yohan Tessier as president and chief operating officer, effective Jan. 1, 2025.

Since joining Mispro in 2007, Tessier has been instrumental in transforming the company’s contract vivarium model into a critical component of the life sciences ecosystem. His strategic vision has driven Mispro’s expansion into leading biotech markets, positioning its facilities as essential amenities within life science campuses and making contract vivarium access an integral part of preclinical research infrastructure.

“Yohan has been a driving force behind Mispro’s evolution and success, and his strategic vision has defined our company as a leader in the contract vivarium space,” said Philippe Lamarre, CEO of Mispro. “His promotion to president and COO reflects our confidence in his ability to lead Mispro into its next phase of growth.”

Tessier has played a pivotal role in expanding Mispro’s footprint by strategically positioning facilities within key life science clusters, ensuring seamless access for biotech and pharmaceutical companies. In addition to leading location strategy and operational efficiencies, he has reimagined vivarium environments by incorporating collaboration spaces, natural light, and color—elements that challenge traditional perceptions of preclinical research facilities. By streamlining operations and transitioning to an all-inclusive space plus services model, he has strengthened Mispro’s role as an indispensable resource for preclinical drug development, further integrating the contract vivarium model into the broader innovation ecosystem.

In his expanded role, Tessier will spearhead high-impact growth initiatives, including forging strategic partnerships with venture capital firms, incubators, and life science real estate leaders to integrate contract vivarium facilities directly into the innovation pipeline of emerging biotech companies. As Mispro expands in metro Boston/Cambridge, the Bay Area, and into San Diego in 2026, his leadership will be key to shaping the company’s continued influence in preclinical research.

About Mispro

Mispro is a leading contract vivarium organization providing biomedical researchers with turnkey, full-service vivarium facilities to conduct preclinical in vivo studies. With locations in metro Boston/Cambridge, New York, Raleigh-Durham (RTP), Philadelphia, South San Francisco, San Carlos, and Montreal, Mispro supports innovation by offering a flexible, cost-effective alternative to outsourcing early-stage studies or internalizing an in-house vivarium. For more information, visit www.mispro.com.

Contacts

Media Contact:
John Fogarty
jfogarty@mispro.com

Mispro


Release Versions

Contacts

Media Contact:
John Fogarty
jfogarty@mispro.com

Social Media Profiles
More News From Mispro

Mispro Becomes Gold Sponsor of LabCentral, Advancing Access to Vivarium Space for Early-Stage Biotech Companies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mispro becomes Gold Sponsor of LabCentral. Mispro to provide integrated contract vivarium space and services to LabCentral resident companies....

Mispro Announces Tenth Boston Location in Cambridge, MA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mispro, a leading contract vivarium organization (CVO), has announced that its newest Metro-Boston facility will open this December on Binney Street in Kendall Square, Cambridge, MA. Strategically positioned in the heart of Kendall Square, a globally recognized hub for biotechnology and pharmaceutical innovation, Mispro’s Binney Street facility will offer turnkey vivarium lab space and comprehensive support services for preclinical in vivo studies. This expans...

Mispro to Open Contract Vivarium in Philadelphia’s UCity Biocluster

PHILADELPHIA--(BUSINESS WIRE)--Mispro, a pioneering contract vivarium organization (CVO), is set to open a full-service vivarium facility in Philadelphia's thriving UCity biocluster in January 2024. Mispro's decision to expand into Philadelphia stems from the rapid growth of the local biopharma sector and the escalating demand for turnkey, yet cost-effective, lab space dedicated to preclinical R&D. Philippe Lamarre, CEO of Mispro, conveyed his excitement about the company’s expansion, empha...
Back to Newsroom